Πρωτεύουσες καρτέλες
Ο κατάλογος των δημοσιεύσεων είναι ενδεικτικός και μπορεί να μην περιλαμβάνει το σύνολο των δημοσιεύσεων.
Circulating leptin in patients with nonalcoholic fatty liver disease-related liver fibrosis: a systematic review and a meta-analysis..
J Gastroenterol Hepatol.
(2024).
Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy..
Semin Cancer Biol. 93, 20-35.
(2023).
Tumor Necrosis Factor-Alpha and Adiponectin in Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma..
Cancers (Basel). 15(21),
(2023).
Innate immunity and nonalcoholic fatty liver disease..
Ann Gastroenterol. 36(3), 244-256.
(2023).
Nonalcoholic fatty liver disease test: an external validation cohort..
Hormones (Athens).
(2023).
Sarcopenia: still in relative definition-penia and severe treatment-penia..
Metabolism. 155717.
(2023).
Letter: higher severe outcomes among Helicobacter pylori-related lean patients with non-alcoholic fatty liver disease and metabolic comorbidities..
Aliment Pharmacol Ther. 57(10), 1186-1187.
(2023).
The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease..
Expert Rev Clin Pharmacol. 1-10.
(2023).
Controlling the Impact of -Related Hyperhomocysteinemia on Neurodegeneration..
Medicina (Kaunas). 59(3),
(2023).
Local and systemic autoimmune manifestations linked to hepatitis A infection..
Acta Gastroenterol Belg. 86(3), 429-436.
(2023).
Wnt/beta-catenin signaling inhibitors and nonalcoholic fatty liver disease: Potential therapeutic implications..
Hepatobiliary Pancreat Dis Int.
(2023).
Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis.
Current Medicinal Chemistry. 30,
(2023).
Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease..
Metabolism. 147, 155676.
(2023).
Nonalcoholic fatty liver disease and Helicobacter pylori infection. Is it time to address this potential relationship?.
Curr Vasc Pharmacol.
(2023).
Potential impact of trained innate immunity on the pathophysiology of metabolic dysfunction-associated fatty liver disease..
Clin Immunol. 256, 109776.
(2023).
Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease..
Ther Clin Risk Manag. 19, 77-96.
(2023).
Impact of nonalcoholic fatty liver disease-related metabolic state on depression..
Neurochem Int. 163, 105484.
(2023).